Skip to main content
TipRanks
Go Ultimate75% OFF

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

33 Followers
DE:EUZ

Eckert & Ziegler Strahlen und Medizintechnik

(XETRA:EUZ)

Select Model
Rating:76.5Outperform
Price Target:EUR 17.50â–²(13.12% Upside)
Action:upgraded
Date:11/16/26

The score is driven primarily by strong financial performance (robust profitability and a low-leverage balance sheet), partially offset by less consistent cash-flow conversion. Technicals are bullish but overbought (high RSI/Stoch), which tempers the outlook. Valuation is reasonable (P/E 17.63) with a modest dividend yield (1.43%).

Positive Factors
Revenue and earnings growthRevenue has expanded materially over several years while profitability remains robust, indicating meaningful business growth rather than scale without earnings. This combination can support continued investment, reinforce market position, and provide a stronger base for earnings generation over the next several quarters.
Negative Factors
Uneven cash conversionCash generation does not fully track accounting earnings, which may reflect working-capital or investment swings. If this pattern persists, reported profit will translate less efficiently into funds available for reinvestment, debt reduction, acquisitions, or shareholder distributions.

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:EUZ+0.14%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 78.99M
Dividend Yield
1.42%
Average Volume (3M)
106.95K
Price to Earnings (P/E)
17.8
Beta (1Y)
1.31
Revenue Growth
4.05%
EPS Growth
36.66%
Country
Germany
Employees
1,116
Sector
General
Sector Strength
55
Industry
Medical - Specialties

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company Description

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of pro...

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary

Strong fundamentals overall: the income statement is solid (Score 86) with materially higher revenue over the period and healthy profitability, and the balance sheet is conservatively positioned (Score 84) with low and improving leverage plus strong ROE. The main drag is cash-flow consistency (Cash Flow Score 73), where operating cash flow trails net income in TTM and historical free cash flow has been volatile.

Income Statement

86Very Positive

Balance Sheet

84Very Positive

Cash Flow

73Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue316.83M311.96M295.85M246.09M222.26M180.44M
Gross Profit151.69M147.21M143.16M116.34M106.78M91.08M
EBITDA97.82M92.13M85.43M59.67M57.90M56.73M
Net Income54.38M48.76M33.28M26.30M29.28M34.53M
Balance Sheet
Total Assets496.57M485.68M442.40M439.36M416.84M347.73M
Cash, Cash Equivalents and Short-Term Investments120.88M128.76M118.36M68.00M82.70M95.02M
Total Debt38.67M44.80M55.34M56.30M49.59M26.97M
Total Liabilities211.22M232.25M217.18M215.27M203.21M155.20M
Stockholders Equity283.90M251.77M223.45M222.18M212.07M187.39M
Cash Flow
Free Cash Flow29.76M34.39M49.38M21.12M3.17M5.00M
Operating Cash Flow52.58M60.41M66.57M46.95M34.30M33.85M
Investing Cash Flow-27.69M-25.93M-16.59M-42.74M-41.04M-23.59M
Financing Cash Flow-26.09M-21.53M-9.99M-9.28M-5.71M-6.06M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

Technical Analysis SentimentPositive
Last Price15.47

Price Trends

50DMA12.88Positive
100DMA13.40Positive
200DMA14.14Positive

Market Momentum

MACD0.57Negative
RSI81.94Negative
STOCH89.93Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Positive. The current price of 15.47 is above the 20-day moving average (MA) of 13.69, above the 50-day MA of 12.88, and above the 200-day MA of 14.14, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 81.94 is Negative, neither overbought nor oversold. The STOCH value of 89.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

DE:EUZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DE:SHLDE:SHL77OutperformEUR 49.09B22.2211.72%2.27%1.09%3.52%
DE:EUZDE:EUZ77OutperformEUR 968.02M17.7820.26%1.42%4.05%36.66%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DE:M3VDE:M3V55NeutralEUR 37.49M27.117.77%4.61%-6.92%-67.82%
DE:SBSDE:SBS54NeutralEUR 333.68M-7.87-18.69%2.19%――
DE:GXIDE:GXI52NeutralEUR 1.07B-2.67-32.84%0.13%8.90%-609.05%

* General Sector Average

Performance Comparison

-20%0%20%40%DE:EUZDE:GXIDE:M3VDE:SBSDE:SHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:EUZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:EUZEckert & Ziegler Strahlen und Medizintechnik15.47-0.15-0.93%
DE:GXIGerresheimer AG31.066.5026.47%
DE:M3VMeVis Medical Solutions20.60-3.30-13.81%
DE:SBSSTRATEC Biomedical27.457.8339.90%
DE:SHLSiemens Healthineers44.003.418.39%
DE:MF6MagForce AG―――
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026